ATE173459T1 - Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien - Google Patents

Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien

Info

Publication number
ATE173459T1
ATE173459T1 AT92905512T AT92905512T ATE173459T1 AT E173459 T1 ATE173459 T1 AT E173459T1 AT 92905512 T AT92905512 T AT 92905512T AT 92905512 T AT92905512 T AT 92905512T AT E173459 T1 ATE173459 T1 AT E173459T1
Authority
AT
Austria
Prior art keywords
pct
propargylamines
inhibitors
sec
hydroxy
Prior art date
Application number
AT92905512T
Other languages
English (en)
Inventor
Peter H Yu
Bruce A Davis
Alan A Boulton
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Application granted granted Critical
Publication of ATE173459T1 publication Critical patent/ATE173459T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/23—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton the carbon skeleton containing carbon-to-carbon triple bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT92905512T 1991-03-01 1992-02-28 Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien ATE173459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/663,018 US5169868A (en) 1991-03-01 1991-03-01 Aliphatic propargylamines as specific mao-b inhibitors

Publications (1)

Publication Number Publication Date
ATE173459T1 true ATE173459T1 (de) 1998-12-15

Family

ID=24660178

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92905512T ATE173459T1 (de) 1991-03-01 1992-02-28 Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien

Country Status (8)

Country Link
US (2) US5169868A (de)
EP (1) EP0573498B1 (de)
JP (1) JP3129733B2 (de)
AT (1) ATE173459T1 (de)
AU (1) AU658611B2 (de)
CA (1) CA2105171A1 (de)
DE (1) DE69227627T2 (de)
WO (1) WO1992015551A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
EP0623344B1 (de) * 1993-05-04 2000-07-26 Ceva Sante Animale Anwendung von Selegilin in Tiermedizin
EP0738149B1 (de) * 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindanderivate und zusammensetzungen hiervon
DE19708461A1 (de) * 1997-02-18 1998-08-27 Meulen Volker Prof Dr Ter Verwendung aminerg wirkender Substanzen zur Herstellung eines Arzneimittels für die Behandlung viraler Infektionen des zentralen Nervensystems
US6111108A (en) * 1997-07-01 2000-08-29 Midwest Research Institute Extraction of biologically active components from Camptotheca acuminata with supercritical fluids
US5840979A (en) * 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
WO1999036076A1 (en) * 1998-01-13 1999-07-22 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
US6809120B1 (en) 1998-01-13 2004-10-26 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
DE69937340T2 (de) * 1998-03-26 2008-07-17 University Of Saskatchewan, Saskatoon Aliphatische aminosäure und aminophosphonsäure, aminonitrile und aminotetrazole als zellulares rettungsmittel
US6984754B1 (en) 1998-03-26 2006-01-10 University Of Saskatchewan Technologies Inc. Aliphatic amino carboxylic and amino phosphonic acids amino nitriles and amino tetrazoles as cellular rescue agents
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US20040062787A1 (en) * 2001-12-17 2004-04-01 Daley William Lionel Therapeutic combination of amlodipineand benazepril/benazeprilat
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (de) * 2003-11-25 2009-03-25 Technion Res & Dev Foundation Zusammensetzungen und verfahren zur behandlung von kardiovaskulären erkrankungen und krankheiten
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
EP2053033A1 (de) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Verbindungen zur Verwendung bei der Abbildung, Diagnose und/oder Behandlung von Erkrankungen des zentralen Nervensystems oder von Tumoren
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
KR101619564B1 (ko) * 2009-04-23 2016-05-10 바이엘 파마 악티엔게젤샤프트 Ｆ-18 표지 ｐｅｔ 추적자에 관한 신규 전구체 분자
CN102791258B (zh) 2010-02-03 2018-05-08 图必制药公司 雷沙吉兰的延长释放制剂及其用途
US8759382B2 (en) 2010-09-29 2014-06-24 Teva Pharmaceutical Industries Ltd. Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB342651A (en) * 1929-10-03 1931-02-03 British Celanese Improvements in the manufacture of artificial filaments, threads & the like by wet spinning methods
GB842651A (en) * 1957-04-01 1960-07-27 Lakeside Lab Inc Novel acetylene compounds and process of preparing same
BE576562A (fr) * 1958-03-21 1959-07-01 Armour & Co Solution stabilisée de chymotrypsine
US3000903A (en) * 1959-09-15 1961-09-19 Lakeside Lab Inc Phenylalkylhydrazines and use as psychotherapeutics
US2997442A (en) * 1960-03-30 1961-08-22 Louise F Peale Lubricating oil composition
FR1453844A (fr) * 1965-03-19 1966-07-22 Soc Ind Fab Antibiotiques Sifa Nouvelles n-propynyl alcoylamines et leurs sels et procédé de préparation
US4201725A (en) * 1974-05-20 1980-05-06 Labaz Secondary amines
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
JPH03176457A (ja) * 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材

Also Published As

Publication number Publication date
EP0573498B1 (de) 1998-11-18
WO1992015551A1 (en) 1992-09-17
JP3129733B2 (ja) 2001-01-31
DE69227627T2 (de) 1999-06-24
US5508311A (en) 1996-04-16
US5169868A (en) 1992-12-08
DE69227627D1 (de) 1998-12-24
CA2105171A1 (en) 1992-09-02
EP0573498A1 (de) 1993-12-15
JPH06505241A (ja) 1994-06-16
AU658611B2 (en) 1995-04-27
AU1323692A (en) 1992-10-06

Similar Documents

Publication Publication Date Title
DE69227627D1 (de) Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
NO308739B1 (no) Imidazolderivater samt medisinsk sammensetning og anti-HIV- sammensetning omfattende samme
DK1424330T3 (da) Aktivator for peroxisom proliferator-responsiv receptor delta
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
KR920014810A (ko) 항균제
DK0607193T3 (da) Antifugale triazolderivater
PE20061159A1 (es) Derivados de acido hidroxibifenilcarboxilico y procedimientos para prepararlos
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
PT1468692E (pt) Utilizacao de 2,6-dialquil-4-sililfenois para o tratamento do xantoma
ES2127762T3 (es) Quinoleinas 2-sustituidas para el tratamiento de las leismaniosis.
FI831431A0 (fi) Bensotiazolinfoereningar
PT97991A (pt) Processo para a preparacao de derivados de 2-(aminoalquil)-5-(arilalquil)-1,3-dioxanos e de composicoes farmaceuticas que os contem
DK1471059T3 (da) 2,4,6-tris(dineopentyl-4'-aminobenzalmalonat)-s-triazin, fotobeskyttende kosmetiske sammensætninger indeholdende denne forbindelse og anvendelse af den nævnte forbindelse
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
SE8303913L (sv) Heterocykliska foreningar
ES2190781T3 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
DK0609281T3 (da) Benzoxazol-, benzothiazol- og benzimidazol-derivater til anvendelse som fungicider
PT100682A (pt) Agentes anti-helminticos derivados de benzimidazole e processo para a sua preparacao
DE69633557D1 (de) Imdazol-derivate, deren herstellung und deren verwendung als s-adenosylmethionin decarboxylase (=samdc) inhibitoren
ES2140393T3 (es) Compuestos de penem.
WO2000024389A3 (en) Benzoquinoline derivatives useful as antibacterial agents
DE69521895D1 (de) Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten
KR880005088A (ko) 제초활성을 갖는 1-카바모일-2-피라졸린 유도체

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties